Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL19534323 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29367581 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29356918 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL131381 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1501478 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL663859 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4177273-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma Inc. (JP) | 2023-05-10 | — | — | EP | disclosed |
| EP-4119582-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma Inc. (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11066468-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3725810-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | Astellas Pharma Inc. (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-20190194318-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10280220-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IBC PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20160287722-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287722-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160200867-A1 | ALKOXYLATION METHODS | NEKTAR THERAPEUTICS | 2016-07-14 | — | — | US | disclosed |
| US-20160200867-A1 | ALKOXYLATION METHODS | NEKTAR THERAPEUTICS | 2016-07-14 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080182816-A1 | Utilizing prodrug technique to couple polysaccharides containing galactose with a parent compound through different bridge linkage to derive conjugates; polysaccharide component protects 5-fluorouracil(5-FU) from absorption in the upper gastrointestinal tract, delivers the 5-FU to colorectal area | TAM JOEMY C | 2008-07-31 | — | — | US | disclosed |
| US-20080182816-A1 | Utilizing prodrug technique to couple polysaccharides containing galactose with a parent compound through different bridge linkage to derive conjugates; polysaccharide component protects 5-fluorouracil(5-FU) from absorption in the upper gastrointestinal tract, delivers the 5-FU to colorectal area | TAM JOEMY C | 2008-07-31 | — | — | US | disclosed |
| US-20080161571-A1 | Process For Producing [1,4'] Bipiperdinyl-1'-Carbonyl Chloride or Hydrochloride Thereof | FERMION OY (FI) | 2008-07-03 | — | — | US | disclosed |
| US-20080161571-A1 | Process For Producing [1,4'] Bipiperdinyl-1'-Carbonyl Chloride or Hydrochloride Thereof | FERMION OY (FI) | 2008-07-03 | — | — | US | disclosed |
| US-20080161572-A1 | Eliminating excess bipiperidinyl-1'-carbonyl chloride after it has reacted with 7-ethyl-10-hydroxy camptothecin and crystallizing the pure irinotecan hydrochloride formed | FERMION OY (FI) | 2008-07-03 | — | — | US | disclosed |
| US-20080103309-A1 | Process for the Manufacturing of 7-Ethyl-10-Hydroxy Camptothecin | FERMION OY (FI) | 2008-05-01 | — | — | US | disclosed |
| US-20080103309-A1 | Process for the Manufacturing of 7-Ethyl-10-Hydroxy Camptothecin | FERMION OY (FI) | 2008-05-01 | — | — | US | disclosed |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | W. C. HERAEUS GMBH (DE) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280220-B2 | Immunoconjugates with an intracellularly-cleavable linkage | CD47, FOLH1, DNPEP | TOP1 1088/4885GLA 1364/4885GAA 377/4885 |
| US-20080182816-A1 | Utilizing prodrug technique to couple polysaccharides containing galactose with a parent compound through different bridge linkage to derive conjugates; polysaccharide component protects 5-fluorouracil(5-FU) from absorption in the upper gastrointestinal tract, delivers the 5-FU to colorectal area | SI, GALE, DPYD | TOP1 806/4885GLA 69/4885GAA 378/4885 |
| US-20160287722-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, FOLH1, DNPEP | TOP1 1088/4885GLA 1364/4885GAA 377/4885 |
| US-20190194318-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, FOLH1, DNPEP | TOP1 1088/4885GLA 1364/4885GAA 377/4885 |
| US-11066468-B2 | Immunoconjugates with an intracellularly-cleavable linkage | CD47, FOLH1, DNPEP | TOP1 1088/4885GLA 1364/4885GAA 377/4885 |
| US-20080161572-A1 | Eliminating excess bipiperidinyl-1'-carbonyl chloride after it has reacted with 7-ethyl-10-hydroxy camptothecin and crystallizing the pure irinotecan hydrochloride formed | DPYD, TOP1, CCDC47 | TOP1 2/4885GLA 4777/4885GAA 3896/4885 |
| US-20080103309-A1 | Process for the Manufacturing of 7-Ethyl-10-Hydroxy Camptothecin | TOP1, TOP2A, DHPS | TOP1 1/4885GLA 4123/4885GAA 3526/4885 |
| US-20080161571-A1 | Process For Producing [1,4'] Bipiperdinyl-1'-Carbonyl Chloride or Hydrochloride Thereof | DHPS, GGPS1, PYCR1 | TOP1 3749/4885GLA 3142/4885GAA 2444/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | TOP1 32/4885GLA 1803/4885GAA 1645/4885 |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | TYMP, PNP, PAICS | TOP1 6/4885GLA 3356/4885GAA 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.